Skip to main content

Vyndamax FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 2, 2019.

FDA Approved: Yes (First approved May 3, 2019)
Brand name: Vyndamax
Generic name: tafamidis
Dosage form: Capsules
Company: Pfizer Inc.
Treatment for: Cardiomyopathy of Transthyretin-Mediated Amyloidosis

Vyndamax (tafamidis) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.

Development Timeline for Vyndamax

DateArticle
May  6, 2019Approval  FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.